GLP1R and type 2 diabetes mellitus: Studies on the primary prevention of HF in patients with T2DM using GLP-1 receptor agonists have yielded mixed results.The LEADER study, an international multicenter, randomized, double-blind, placebo-controlled trial involving 9,340 patients with T2DM at high cardiovascular risk (81.3% of whom had a history of cardiovascular disease), compared the long-term effects of liraglutide (1.2 mg and 1.8 mg) to those of placebo over a mean follow-up of 3.8 years.